Table 9.
Overview of TEAEs—roxadustat through Week 52 or end of study (safety analysis set)
Parameter | Roxadustat |
Roxadustat |
Pooled roxadustat |
---|---|---|---|
(comparative) (n = 131) |
(reference) (n = 70) |
(n = 201) |
|
n (%) | n (%) | n (%) | |
TEAE | 115 (87.8%) | 63 (90.0%) | 178 (88.6%) |
Serious TEAE | 34 (26.0%) | 19 (27.1%) | 53 (26.4%) |
TEAE leading to withdrawal of treatment | 26 (19.8%) | 14 (20.0%) | 40 (19.9%) |
Death | 0 | 2 (2.9%) | 2 (1.0%) |
TEAE, treatment-emergent adverse event.